INTRODUCTION {#s1}
============

Obesity is a global epidemic disorder with a multifaceted etiology, including genetics and environmental factors \[[@r1]\]. The gut microbiota, the microbial community inhabiting the intestine, has been recently implicated as an important environmental factor in obesity and its related metabolic disorders \[[@r2],[@r3],[@r4]\]. The most abundant phyla of the human gut microbiota are Firmicutes and Bacteroidetes, the ratio of which is strongly associated with obesity \[[@r2]\]. It has been shown that the Bacteroidetes to Firmicutes ratio decreases in obesity but increases after weight loss following gastric bypass or calorie restriction \[[@r5]\]. However, some studies have reported inconsistent findings, and these differences should be investigated in lower taxonomic ranks \[[@r6], [@r7]\]. The gut microbiota is considered to be an endocrine organ because of its comprehensive metabolic ability and its extensive genes that influence the host \[[@r8]\]. Recent studies indicate that the obesity-related intestinal microbiota leads to alterations in some circulating metabolites and are associated with fasting levels of some metabolites, such as amino acids, fatty acids, lipids, and glucose \[[@r9], [@r10]\]. The gut microbiota releases metabolites which can be passed through the intestinal barrier and eventually biotransformed by the host \[[@r11]\]. Metabolomics, the systematic study of low-molecular-weight molecules produced in biochemical pathways, is a strong method for recognition of the crosstalk between the gut microbiota and host metabolism \[[@r12]\]. Gut microbial species are the origin of key features of the serum metabolite profile associated with metabolic disorders, including obesity, insulin resistance, and cardiovascular diseases \[[@r9], [@r13]\]. The process used in metabolomics surveys is classified into five major phases: sample collection, sample preparation, data acquisition, data analysis, and biological interpretation of the findings \[[@r14]\]. There are many targeted and untargeted metabolites profiling techniques capable of quantifying polar metabolites and molecular lipids present in biological samples, such as blood, urine and feces \[[@r15]\]. The most prevalent analytical techniques applied for the determination of the metabolic profile of a biological sample are liquid chromatography-mass spectrometry (LC-MS), gas chromatography-mass spectrometry (GC-MS), and nuclear magnetic resonance (NMR) \[[@r16]\].

Specific metabolites are strongly associated with gut microbial community structure, and some of these correlations are specific to the overweight or obesity state \[[@r17], [@r18]\]. Therefore, we performed this systematic review to summarize all human studies that characterized the gut microbiota-related metabolites in overweight and obese individuals or focused on correlations between metabolites and gut microbiota in obesity.

METHODS {#s2}
=======

Search strategy and study selection
-----------------------------------

PubMed, Web of Science, and Scopus databases were searched for all human studies focused on the gut bacteria-related metabolites in obesity. The search was restricted to English language studies with no restriction regarding publication date up to July 2018. The search terms included the following: Metabolom\*, metabonom\*, metabolite\*, "metabolic profiling", "metabolic profile" AND "gut microbiota", "intestinal microbiota", "faecal microbiota", "gut microbiome", "intestinal microbiome", "faecal microbiome", "gut microbial profile", "faecal microbial profile", "gut flora" AND obesity, overweight, obese, adiposity.

Two researchers independently screened titles, abstracts, and then full-text articles to lessen selection bias. Disagreements between the two researchers were resolved by discussing until reaching consensus. Moreover, other relevant references in the selected articles were also reviewed. Targeted and untargeted metabolomics approaches were both included in the selection strategy. Low-molecular-weight (\<1,000 Da) metabolites related to gut microbiota which were significantly up- or downregulated in overweight and obese individuals compared with lean, healthy control subjects were the primary outcomes of interest of this systematic review. Some literature, including in vitro studies, animal studies, reviews, and studies conducted on nonobese hosts, were excluded from the systematic review. The present study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

Data extraction
---------------

Relevant data were extracted from the included studies by two researchers separately. Disagreements between the two investigators were resolved by discussion and consensus. The following information was extracted from the studies: authors; publication year; country of origin; study design; characteristics of the participants, including gender, age, ethnicity, and body mass index (BMI) range; fecal microbiota analysis method, platforms used for metabolites profiling; and the metabolites found to correlate with gut microbiota.

RESULTS {#s3}
=======

The search yielded 2,137 articles (PubMed, 738; Scopus, 692; Web of science, 697; hand searching, 10), of which 2,125 were excluded because they were duplicates, irrelevant or animal studies, or reviews or they were missing outcome data ([Fig. 1](#fig_001){ref-type="fig"}Fig. 1.Flow diagram of the systematic literature search.). Ultimately, 12 human studies successfully met the search criteria and were included in this systematic review. All studies were published between 2010 and 2018 ([Table 1](#tbl_001){ref-type="table"}Table 1.Gut microbiota-derived metabolites found at abnormal levels and correlations between metabolites and gut bacteria in obesityReferencesParticipantsBiofluidPlatformFecal microbiota analysis methodCorrelations between metabolites and gut bacteriaDifferences in metabolites and gut microbiota between obese and controlCalvani *et al.* (2010) \[[@r25]\]15 morbidly obese insulin-resistant male patients and 10 age-matched controlsUrine samplesUntargeted: high-resolution proton NMR (1H NMR) spectroscopy for gut microbiome-derived metabolites\-- Correlation between 2-hydroxyisobutyrate and *Faecalibacterium prausnitzii*↑2-hydroxyisobutyrate in obese\
↓ hippuric acid, trigonelline and xanthine in obeseTiihonen *et al.* (2010) \[[@r21]\]20 obese subjects and 20 normal weight subjectsFecal samplesTargeted: GC--MS for phenolic and acidic compounds, GC for protein and fat and high pH ion exchange chromatography (HPLC) and a pulsed electrochemical detector for soluble and insoluble carbohydratesQuantitative real-time PCR-↑ Branched-chain fatty acids, phenolic acids, lactic acid, 2-methylbutyric acid, valeric acid, isovaleric acid, 3-OH-benzenepropanoic acid, di- and hydroxy acids in obese subjects\
↑sulphate-reducing bacteria and *Bacteroides* in normal weight subjectsPayne *et al.* (2011) \[[@r23]\]15 obese and 15 normal-weight Swiss childrenFecal samplesTargeted: high pressure liquid chromatog­raphy (HPLC) for SCFA, branched chain fatty acids and intermediate metabolitesqPCR and temperature gradient gel electrophoresis (TGGE)- Correlations between lactate and butyrate and lactate-utilizing butyrate-producing species including clostridial cluster XIVa species *Eubacterium hallii* and *Anaerostipes caccae* in obese children.\
- Correlations between propionate and Gram-negative *Bacteroides--Prevotella* group and Gram-positive species of clostridial cluster IX.↑ isobutyrate, formate, butyrate and propionate in obese\
↑ lactate and valerate in normal-weight subjectsRaman *et al.* (2013) \[[@r26]\]30 obese NAFLD patients and 30 healthy controlsFecal samplesTargeted: gas chromatography--mass spectrometry for volatile organic compoundsMultitag pyrosequencing-↑ *Lactobacillus* species and phylum Firmicutes (*Lachnospiraceae*; genera, *Dorea*, *Robinsoniella*, and *Roseburia*) in obese\
↓ *Ruminococcaceae*; genus, *Oscillibacter* in obese\
↑ Fecal ester compounds including aliphatic esters of ethanoic, propanoic, butanoic and pentanoic acids in obeseBondia-Pons *et al.* (2014) \[[@r19]\]16 Finnish monozygotic twin pairs discordant for weight and 9 concordant pairsPlasmaUntargeted: Two-dimensional gas chromatography coupled to time-of-ﬂight mass spectrometry (GC_GC-TOFMS) for polar metabolites and ultraperformance liquid chromatography coupled to quadrupole-TOFMS (UPLC-QTOFMS) for molecular lipids\
Targeted: UPLC coupled to triple-quadrupole MS (UPLC-QqQMS) for bile acids (BAs)Denaturing gradient gel electrophoresis (DGGE)- Negative correlations between biﬁdobacterial diversity and clusters of carbohydrates and amino acids and long-chain TGs.\
- Positive correlations between *Lachnospiraceae* diversity and clusters of amino acids and TCA cycle metabolites.\
- Positive correlations between *Bacteroides* diversity and clusters of BA lithocholic acid (LCA) and phosphatidyl ethanolamines.\
- Positive correlations between *Ruminococcaceae* diversity and clusters of long-chain polyunsaturated fatty acid (PUFA)-containing TGs.-Druart *et al.* (2014) \[[@r29]\]Obese womenSerumTargeted: gas--liquid chromatography for PUFA-derived bacterial metabolitesphylogenetic microarray and qPCR analysis of 16S rDNA- Positive correlations between CLnA cis-9,trans-11,cis-15-18:3 and bifidobacteria, *E. ventriosum* and lactobacilli.\
- Positive correlations between CLA cis-9,cis-11-18:2 and bifidobacteria and *Eubacterium ventriosum*.\
- Positive correlations between CLA trans-9,trans-11-18:2 and *E. ventriosum*.-Ahmad *et al.* (2016) \[[@r28]\]50 participants with normal BMI (18.5 to \<25 kg/m^2^) and 50 obese (BMI \> 30 kg/m^2^)Fasting plasma and serum samples and urine specimensUntargeted: NMR-based metabolic profiling\_-↑urinary excretion of hippurate, phenylacetylglutamine, 4-cresyl sulfate and formate in the lean group\
↑urinary excretion of metabolites associated with bacterial degradation of choline such as TMA and DMA in the obese group\
↓urinary excretion of indoxyl sulfate in the obese groupLiu *et al.* (2017) \[[@r9]\]257 young Chinese obese individuals and lean controlsSerumUntargeted: high performance liquid chromatograph (HPLC)-MS\
Targeted: ultra-high performance liquid chromatog­raphy (UHPLC) coupled to a Shimadzu 8050 Triple Quad mass spectrometry for amino acidsshotgun sequencing- Negative correlations between phenylalanine, tyrosine, leucine, isoleucine and valine and *Bacteroides* species including *B. thetaiotaomicron*, *B. intestina­lis*, *B. ovatus* and *B. uniformis*\
- Negative correlations between glutamate and *B. thetaiotaomicron*\
- Positive correlations between glutamate and *Ruminococcus* sp., *D. longicatena*, *C. comes*↑Phenylalanine, tyrosine, leucine, isoleucine, valine and glutamate in obeseOrg *et al.* (2017) \[[@r20]\]531 middle-aged Finnish menSerum and plasmaTargeted: nuclear magnetic resonance (NMR) spectroscopy platform for lipids, lipoproteins, fatty acids, amino acids, ketone bodies and glycolysis precursor molecules and liquid chromatography with on-line tandem mass spectrometry (LC-MS/MS) for TMAO, choline, betaine, and carnitine16S ribosomal RNA gene sequencing- correlation between acetate and microbial diversity\
- Positive correlation between glutamine, glycated hemoglobin and acetate and microbial richness\
- Positive correlations between acetate and phylum Tenericutes, family *Christensenellaceae*, unclassified *Clostridales*, *Peptococcaceae*, and several members of family *Clostridiaceae*\
- Negative correlations between acetate and *Blautia* and *Oscillospira*\
- Positive correlations between *Blautia* and saturated, monounsaturated fatty acids, pyruvate and glycerol, isoleucine and valine\
- Negative correlations between *Blautia* and polyunsaturated fatty acids, including omega-3, 22:6 docosahexaenoic acid, omega-6, and 18:22 linoleic acids\
- Positive correlation between glutamine and *Clostridales*\
- Negative correlations between isoleucine and valine and *Christensenellaceae*\
- Positive correlation between TMAO and *Peptococcaceae* and *Prevotella*\
- Negative correlation between TMAO and *Faecalibacterium prausnitzii*↑ *Collinsella* with higher levels of glycerol and phenylalanine in obese subjects\
↑ phylum Tenericutes and family *Christensenellaceae* with higher levels of acetate in normal-weight subjects\
↑ *Blautia* with higher levels of BCAA (isoleucine and leucine), alanine, glycerol, and pyruvate in obese subjects\
↓*Methanobacteriaceae* with higher levels of glycerol and total and monounsaturated fatty acid in obese subjectsHouttu *et al.* (2017) \[[@r22]\]52 overweight and 47 obese pregnant women in early pregnancySerumUntargeted: high-throughput proton NMR metabolomics platform for lipids, amino acids and GlycA16S ribosomal RNA gene sequencing- Correlations between *Prevotella copri* and branched chain amino acids↑several VLDL subclasses and isoleucine, leucine, valine, phenylalanine and GlycA in obese pregnant women.\
↓ lipids in certain HDL subclasses and omega-6 fatty acid, 18:2 linoleic acid in obese pregnant women\
↑bacterial family *Prevotellaceae*, genus *Prevotella* and species *copri* in obese pregnant women\
↓ *Prevotella uniformis* in obese pregnant womenLópez-Contreras *et al.* (2017) \[[@r27]\]67 normal-weight and 71 obese children aged 6--12 yearsSerumTargeted: mass spectrometry for amino acids16S rRNA sequencing- Negative correlation between *Bacteroides eggerthii* and citrulline\
- Negative correlation between *Bacteroides plebeius* and unclassified *Christensenellaceae* and phenylalanine\
- Negative correlation between unclassified *Christensenellaceae* and arginine, methionine and ornithine↑ BCAA, leucine and valine, aromatic amino acids, phenylalanine and tyrosine in obese children\
↑*B. plebeius* and unclassified *Christensenellaceae* in normal-weight childrenPiening *et al.* (2018) \[[@r24]\]23 healthy participants with BMI 25--35 kg/m^2^ No control groupPlasmaUntargeted: LC-MS16S ribosomal RNA gene sequencing and whole genome metagenomic shotgun sequencing- Correlation between *Bacteroides vulgatus* and BCAA metabolism\
- Positive correlation between antioxidant 3-indolepropionic acid and Proteobacteria in the insulin resistant subjects\
- Positive correlation between N6-trimethyllysine and phylum Proteobacteria in the insulin sensitive subjects-).

Most of the included studies compared metabolites in overweight or obese individuals with normal weight controls in different populations, including Chinese \[[@r9]\], Finnish \[[@r19],[@r20],[@r21],[@r22]\], Swiss \[[@r23]\], American \[[@r24]\], Italian \[[@r25]\], Canadian \[[@r26]\], Mexican \[[@r27]\], and Arabian \[[@r28]\] populations. The age range varied from school-age children \[[@r23], [@r27]\] to young and middle age adults \[[@r9], [@r19],[@r20],[@r21], [@r24],[@r25],[@r26], [@r28], [@r29]\]. One study investigated obese women in early pregnancy \[[@r22]\]. The biological samples used in these studies consisted of serum and plasma samples (in 7 studies), fecal samples (in 3 studies), and urine samples (in 2 studies). The analytical platforms applied for targeted metabolic profiling consisted of ultra-high-performance liquid chromatography (UHPLC) coupled to triple quadrupole mass spectrometry (UPLC-QqQMS) \[[@r9], [@r19]\], gas-liquid chromatography \[[@r21], [@r29]\], high-pressure liquid chromatography (HPLC) \[[@r21], [@r23]\], nuclear magnetic resonance (NMR) spectroscopy \[[@r20]\], liquid chromatography with on-line tandem mass spectrometry (LC-MS/MS) \[[@r20]\], gas chromatography-mass spectrometry (GC-MS) \[[@r21], [@r26], [@r27]\], and a pulsed electrochemical detector \[[@r21]\]. The platforms for untargeted metabolic detection included gas chromatography coupled to time-of-ﬂight mass spectrometry (GC_GC-TOFMS) \[[@r19]\], ultra-performance liquid chromatography coupled to quadrupole-TOFMS (UPLC-QTOFMS) \[[@r19]\], HPLC-MS \[[@r9]\], high-throughput proton NMR metabolomics \[[@r22]\], LC-MS \[[@r24]\], high-resolution proton NMR (1H NMR) spectroscopy \[[@r25]\], and NMR-based metabolic profiling \[[@r28]\]. The most used method for fecal microbiota analysis was 16S ribosomal RNA amplicon sequencing \[[@r20], [@r22], [@r24], [@r27]\], and the other techniques included shotgun sequencing \[[@r9], [@r24]\], quantitative real-time PCR \[[@r21], [@r23], [@r29]\], denaturing gradient gel electrophoresis (DGGE) \[[@r19]\], phylogenetic microarray \[[@r29]\], temperature gradient gel electrophoresis (TGGE) \[[@r23]\], and multi-tag pyro-sequencing \[[@r26]\].

DISCUSSION {#s4}
==========

Metabolites related to gut microbiota in obesity
------------------------------------------------

In this systematic review, we categorized several metabolites related to gut microbiota in obesity to simplify evaluation of potential mechanisms.

### Amino acids and metabolites produced from bacterial degradation of amino acids

Gut microbiota manipulate several amino acids (AAs) from dietary or endogenous proteins. These amino acids have a role in the synthesis of metabolic end products produced by the gut microbiota. Therefore, alteration of the gut bacterial composition in obese subjects can play an important role in susceptibility to metabolic disorders by affecting amino acid bioavailability to the host.

#### Branched-chain and aromatic amino acids

Some kinds of amino acids, including branched-chain amino acids (BCAAs)---valine, leucine, and isoleucine---and aromatic amino acids (AAAs)---phenylalanine, tyrosine, and tryptophan---have been reported as a risk factor for metabolic disorders, including obesity, insulin resistance, diabetes, and fatty liver \[[@r30],[@r31],[@r32]\]. With respect to obesity, Liu *et al.* \[[@r9]\] found that the serum levels of AAAs, glutamate, and BCAAs increased in obese subjects. They showed that the gut microbiota of obese individuals may have a higher capacity for production of these amino acids in comparison with lean controls \[[@r9]\].

The concentrations of aromatic amino acid-derived microbial metabolites, including benzoic acid (BA), phenylacetic acid (PAA), phenylpropionic acid (PPA), p-hydroxybenzoic acid (p-HBA), p-hydroxyphenylacetic acid (p-HPAA), 3,4-dihydroxyphenylacetic acid (3,4-DHPAA), indoleacetic acid (IAA), indole propionic acid (IPA), and 5-hydroxyindoleacetic acid (5-HIAA), which are produced through deamination, transamination, decarboxylation, and dehydrogenation reactions, are altered in metabolic disorders \[[@r33]\]. In a recent animal study, Konopelski *et al.* \[[@r34]\] found that a tryptophan-rich diet reduced weight gain in rats compared with a control group via an increase in production of gut bacteria-derived indole propionic acid from tryptophan. This evidence suggested the potential role of gut microbiota-produced metabolites in weight management \[[@r34]\]. In response to feeding a high-fat diet to rat models, metabolism and elimination of p-HPAA, a metabolite produced from tyrosine by gut microbiota, altered in such a way that the p-HPAA concentration decreased in urine while it increased in serum and feces. p-HPAA can be further metabolized to p-cresol through decarboxylation by *Clostridium difficile*. These alterations suggest the underlying mechanisms of accumulation of p-cresol and overgrowth of *C. difficile* in obesity \[[@r35]\]. Furthermore, an animal experiment reported that 3,4-DHPAA, which could protect against pancreatic β-cell dysfunction, increased in obese rats as a potential protection in response to obesity \[[@r36]\]. Moreover, the urinary concentration of the indolic compound 5-HIAA, a clinical indicator of gastrointestinal carcinoid tumors, was elevated in obesity by the monoamine oxidase activity of *Escherichia coli* \[[@r37]\].

Org *et al.* \[[@r20]\] and Piening *et al.* \[[@r24]\] also showed higher serum and plasma levels of BCAAs and phenylalanine in obese subjects and individuals with high insulin resistance values. Bondia-Pons *et al.* \[[@r19]\] revealed that plasma BCAAs were increased in heavier twins compared with leaner co-twins in the fasting state. These amino acids were negatively correlated with *Bacteroides* species, including *B. thetaiotaomicron*, *B. intestinalis*, *B. ovatus*, and *B. uniformis* \[[@r9]\], and *Christensenellaceae* \[[@r20]\]. It has been demonstrated that *B. thetaiotaomicron* and *B. ovatus* can ferment AAAs to produce phenylacetic acid \[[@r38]\]. Piening *et al.* \[[@r24]\] showed a correlation between BCAAs and *B. vulgatus*, which has been shown to be a mediator between BCAA metabolism and insulin resistance \[[@r13]\]. Altogether, the changes in gut microbiota, especially the depletion of species from the *Bacteroides* genus in obese individuals, may be related to the higher concentration of AAAs and BCAAs in circulation \[[@r19]\]. These amino acids are known risk factors for insulin resistance, hyperglycemia, hyperlipidemia, elevated circulating inflammatory factors, diabetes, and cardiovascular diseases \[[@r9], [@r39], [@r40]\]. They may also directly promote insulin resistance, possibly by disconnecting insulin signaling in skeletal muscle \[[@r41]\]. Recent studies have indicated that ribosomal protein S6 kinase 1 (S6K1) is sensitive to both insulin and some nutrients, including amino acids, and that amino acids also negatively affect insulin signaling through phosphorylation of insulin receptor substrate 1 (IRS1) \[[@r42]\].

In a study on overweight and obese women in early pregnancy, Houttu *et al.* \[[@r22]\] showed that the serum concentrations of BCAAs and phenylalanine were significantly higher in the obese pregnant women compared with the overweight ones. They also observed a higher abundance of *Prevotella copri* and a lower abundance of *Prevotella uniformis* in obese compared with overweight pregnant women \[[@r22]\]. However, the findings of this study could have been influenced by the fact that the gut microbiota composition may change during pregnancy \[[@r43]\]. *Prevotella copri*, which belongs to the phylum Bacteroidetes, is associated with biosynthesis of BCAAs and subsequent development of insulin resistance \[[@r13]\]. Ottosson *et al.* \[[@r44]\] showed that higher abundances of all BCAAs and byproducts of BCAA metabolites in plasma, such as branched-chain keto acids (3-methyl-2-oxovalerate, a-ketoisovalerate, and a-ketoisocaproate) and short-chain acylcarnitines (propionylcarnitine and isovalerylcarnitine), were correlated with higher BMI. They revealed correlations between four gut microbiota genera (*Blautia*, *Dorea*, *Ruminococcus*, and *SHA-98*) and BCAAs and glutamate, which are BMI-predictive metabolites. Therefore, these metabolites could be underlying mechanisms connecting gut microbiota and obesity. Three of these genera, *Blautia*, *Dorea*, and *Ruminococcus*, are members of the *Lachnospiraceae* family, one of the most abundant families in the gut microbiota. Two bacterial genera, *SHA-98* and a genus in the *Rikenellaceae* family, were correlated with a lower BMI \[[@r44]\]. *Dorea* and *Ruminococcus* have been found to be connected to metabolic syndrome and weight gain \[[@r45], [@r46]\].

#### Glutamate

The other important gut microbiota-derived AA in obesity is glutamate. Glutamate is a secondary product of the first step of BCAA catabolism. It is significantly related to obesity and gut bacterial genera, including *Blautia*, *Dorea*, *Ruminococcus*, and *SHA-98* \[[@r44]\]. Glutamate has been shown to exhibit the most remarkable increase in obese individuals compared with lean controls \[[@r9], [@r20]\]. The serum concentration of glutamate exhibited positive correlations with obesity features, such as BMI, waist to hip ratio (WHR), waist circumstance (WC), insulin resistance, and triacylglycerol \[[@r9]\]. Positive correlations were observed between glutamate and *Ruminococcus* spp., *Dorea longicatena, Coprococcus comes* \[[@r9]\], and *Clostridiales* \[[@r20]\]. A recent survey revealed that *B. thetaiotaomicron* colonization increases the levels of mRNAs encoding glutamate transporter and glutamate decarboxylase in epithelial cells, which may influence host glutamate levels \[[@r47]\]. *Dorea longicatena* expression is associated with obesity and increased levels of glutamate \[[@r44]\]. The level of *B. thetaiotaomicron*, a glutamate-fermenting species, decreases in the gut microbiota of obese subjects. Moreover, serum glutamate was shown to be inversely correlated with the abundance of *B. thetaiotaomicron*, which possesses genes encoding glutamate decarboxylase. Therefore, the depletion of *B. thetaiotaomicron* may contribute to the higher circulating concentration of glutamate in obesity \[[@r9]\].

It has been documented that glutamate, which is used as a common food additive, is able to induce obesity when administered to rodents \[[@r48]\]. Excessive glutamate consumption has been shown to be positively correlated with overweight in Chinese adults \[[@r49]\]. On the other hand, some studies indicated a protective effect of glutamine versus glutamate and demonstrated that glutamine supplementation altered the gut microbiota composition and improved glucose tolerance and obesity \[[@r32], [@r50]\]. Glutamine is essential for maintaining the overall nitrogen balance by providing mediators to the tricarboxylic acid cycle and for its ammonia carrying potential \[[@r51]\]. The utility of glutamine in metabolic impairments could be due to mechanisms such as higher release of glucagon-like peptide 1 (GLP-1), externalization of glucose transporter type 4 (GLUT-4), transcription of insulin-dependent enzymes, pancreatic beta-cell insulin secretion, and insulin sensitivity of adipose tissue \[[@r52]\]. Glutamate exhibited positive correlations with 16 obesity-enriched metagenomic linkage groups (MLGs) and negative correlations with 18 control-enriched MLGs that harbored genes encoding enzymes involved in glutamate metabolism \[[@r9], [@r53]\]. In particular, obesity-enriched *Ruminococcus* spp., *Dorea longicatena,* and *Coprococcus comes*, which possessed genes encoding enzymes required to produce glutamate from glutamine, were positively correlated with circulating glutamate levels and negatively correlated with glutamine levels \[[@r9]\]. These observations suggest that the levels of glutamate and glutamine in circulation may reflect the changes in the abundance of these bacterial species.

Altogether, these data suggest that amino acid metabolism by gut microbial species may modulate the levels of circulating amino acids that are correlated with obesity and its metabolic complications.

#### Other amino acids and related metabolites

Negative correlation has been observed between some amino acids, including arginine, methionine, and ornithine, and unclassified *Christensenellaceae*, a gut microbial species associated with lower risk of obesity \[[@r27]\]. Other studies have reported higher levels of *Christensenellaceae* in subjects with normal weights \[[@r54], [@r55]\]. It has also been shown that germ-free mice transplanted with fecal samples incubated with *Christensenella minuta*, a cultured member of the *Christensenellaceae* family, gained significantly less weight than mice treated with unamended stool \[[@r55]\]. However, the underlying mechanism of the effect of *Christensenellaceae* on BMI of the host is unclear.

Besides the mentioned AAs, two AA-related metabolites, 3-indolepropionic acid and N6-trimethyllysine, were also evaluated in a study by Piening *et al.* \[[@r24]\]. They revealed that in insulin-resistant subjects, the plasma level of 3-indolepropionic acid was positively associated with the abundance of Proteobacteria, a phylum that has been shown to increase in obese subjects \[[@r56]\]. N6-trimethyllysine was also positively associated with the Proteobacteria exclusively in insulin-sensitive individuals \[[@r24]\]. 3-Indolepropionic acid is a microbial fermentation product from tryptophan which could be a potential drug target for the management of insulin resistance \[[@r57]\]. This metabolite has been shown to be associated with insulin resistance \[[@r13]\]. N6-trimethyllysine, a methylated derivative of lysine, is a precursor for L-carnitine biosynthesis, which improves glucose tolerance and increases total energy expenditure in obesity \[[@r58]\]. These findings show that there are microbial differences between insulin-resistant and insulin-sensitive subjects and that they are related to differences in the metabolism of the host.

The other AA-derived metabolite is indoxyl sulfate, a metabolite of dietary L-tryptophan, which is catalyzed by tryptophanase produced by gut microbiota \[[@r59]\]. Ahmad *et al.* \[[@r28]\] reported decreased excretion of indoxyl sulfate in obese subjects. An inverse relationship of indoxyl sulfate with BMI has also been shown in other animal and human studies \[[@r60], [@r61]\]. Furthermore, it has been shown that *Bifidobacterium* can metabolize indole to form indoxyl sulfate \[[@r62]\]. So, the lower abundance of *Bifidobacterium* in obese subjects can explain the low levels of indoxyl sulfate in overweight/obese individuals.

### Lipids and lipid-like molecules

Alterations in gut microbiota have been shown to be associated with lipid and lipid-like metabolites which may affect lipid metabolism and obesity by increasing substrates for energy metabolism in the liver and peripheral tissues \[[@r63]\]. Increased levels of lipids and free fatty acids are known risk factors for metabolic syndrome, insulin resistance, and obesity, but different types of lipids have been shown to exert contradictory metabolic effects \[[@r64], [@r65]\].

#### Short-chain fatty acids

The important gut microbiota-derived lipids which might affect energy balance and weight changes in humans are short-chain fatty acids (SCFAs) \[[@r2]\]. SCFAs (acetate, propionate, and butyrate) resulting from the colonic fermentation of digestion-resistant starch may provide an estimated additional 10% daily dietary energy to the host and can be used for de novo hepatic triglyceride and glucose synthesis \[[@r66]\]. Moreover, SCFAs could have a role in releasing satiety hormones \[[@r67]\]. They have been suggested to be signaling molecules for production of peptide YY (PYY) by enteroendocrine cells and thus decrease gut motility and further increase SCFA absorption and energy extraction from the gut lumen \[[@r68]\]. SCFAs, especially butyrate, significantly increase plasma levels of gastric inhibitory peptide (GIP), glucagon-like peptide 1 (GLP-1), PYY, insulin, and amylin, which would have a net effect on slowing digestion and nutrient intestinal transit, promoting satiety, and increasing plasma insulin. Acetate is reported to increase leptin released by fat cells; propionate increases G-protein-mediated secretion of PYY and GLP-1 in the gut and controls the rates of lipolysis and lipogenesis in fat cells \[[@r69]\]. However, there are inconsistent findings regarding the role of these compounds in obesity and its complications. Metabolic analyses of the feces of obese and normal-weight adults have identified increased levels of SCFAs in obese individuals \[[@r7]\]. Payne *et al.* \[[@r23]\] showed that fecal SCFAs, including isobutyrate, formate, butyrate, and propionate, increased in obese children but that lactate and valerate were elevated in normal-weight subjects. They found a correlation between lactate and butyrate with lactate-utilizing and butyrate-producing species, including clostridial cluster XIVa species *Eubacterium hallii* and *Anaerostipes caccae*, in obese children. They also showed correlations between fecal propionate and the Gram-negative *Bacteroides*--*Prevotella* group and Gram-positive species of clostridial cluster IX \[[@r23]\]. These species may contribute to glucose and lipid metabolism through the produced metabolites, including propionate and acetate, that participate in gluconeogenesis and synthesis of cholesterol and de novo synthesis of lipids, respectively \[[@r70]\]. *Prevotella uniformis* has been found to decrease metabolic and immune dysfunction by affecting macrophage and dendritic cell function and intestinal dysbiosis in obese mice consuming a high-fat diet \[[@r71]\].

The major microbiota phyla affecting SCFA production in the gut are Firmicutes and Bacteroidetes \[[@r72]\]. *Blautia* is a common gut habitant belonging to the family *Lachnospiraceae*, which is one of the major taxonomic groups of the human gut microbiota that degrade complex polysaccharides to SCFAs. It has the ability to ferment a large variety of organic substrates, enabling flexible growth in the colon. Different bacterial species in the *Blautia* genus have been associated with obesity \[[@r73]\]. There is an association between *Blautia* and human genetic variants in a genomic region that has been associated with obesity and BMI \[[@r74]\]. Furthermore, SCFAs have been reported to be positively associated with *Prevotella*, *Alistipes*, and *Barnesiella* and negatively correlated with *Bacteroides* and *Enterococcus*. It is notable that *Prevotellaceae* has been shown to increase in obese individuals \[[@r75]\].

#### Triglycerides, cholesterol, and saturated and unsaturated fatty acids

Some microbial species have been found to alter the blood triglycerides and cholesterol fatty acids and thus can also influence host energy and lipid metabolism by regulating serum lipid levels. Org *et al.* \[[@r20]\] showed that *Blautia* was positively correlated with serum saturated fatty acids (SFAs) and monounsaturated fatty acids (MUFAs) but negatively correlated with acetate and polyunsaturated fatty acids (PUFAs), including omega-3, 22:6 docosahexaenoic acid, omega-6, and 18:22 linoleic acids. They also showed an increased abundance of *Blautia* in individuals with high BMI levels. The serum triglyceride (TG) level was associated with higher abundances of genus *Methanobrevibacter* from Archaea and Tenericutes, a phylum of bacteria. However, *Peptococcaceae* and *Christensenellaceae* were associated with lower TG levels \[[@r20]\].

Tiihonen *et al.* \[[@r21]\] showed increased fecal concentrations of BCFAs, including 2-methylbutyric acid and isovaleric acid, in obese subjects. BCFAs synthesized from proteins and amino acids are precursors of long-chain fatty acids and aldehydes. It should be noted that some gut bacteria, such as *Bacteroides succinogenes*, need both branched-chain volatile fatty acids (e.g., isobutyric acid) and straight-chain fatty acids (e.g., valeric acid) for growth. BCFAs can also be used as nitrogen donors for other important amino acids, such as glutamine and alanine, which both serve as an energy source for the gastrointestinal tract \[[@r76], [@r77]\].

Houttu *et al.* \[[@r22]\] showed that serum lipids in certain high-density lipoprotein cholesterol (HDL-C) subclasses, omega-6 fatty acid, 18:2 linoleic acid, the ratio of PUFAs to total fatty acids, and the estimated degree of unsaturation of fatty acids were decreased but that several very-low-density lipoprotein cholesterol (VLDL-C) subclasses were increased in obese pregnant women.

Bondia-Pons *et al.* \[[@r19]\] found a negative correlation between Biﬁdobacterial diversity and plasma long-chain TGs and positive correlations between *Ruminococcaceae* diversity and clusters of PUFA-containing TGs, sphingomyelins, and other phospholipids. The postprandial changes of medium-chain fatty acids and monounsaturated fatty acids containing TGs were both negatively associated with liver fat and intra-abdominal fat. Postprandial changes of TGs with odd-chain fatty acids in plasma were negatively associated with the diversity of *Lachnospiraceae*, thus suggesting that this group may be involved in the metabolism of dietary lipids. Furthermore, the diversity of *Bacteroides* spp. was associated negatively with postprandial changes of unsaturated medium-chain TGs in plasma \[[@r19]\].

Conjugated linolenic acid (CLnA) and conjugated linoleic acid (CLA) are two important PUFA-derived metabolites with proven beneficial effects on weight loss. Druart *et al.* \[[@r29]\] showed positive correlations between the serum concentrations of both CLnA and CLA and *Bifidobacterium*, *Eubacterium ventriosum*, and *Lactobacillus* abundances. They also found negative correlations between these metabolites and the blood cholesterol profile, suggesting a potential beneficial effect of some PUFA-derived bacterial metabolites \[[@r29]\]. The effects of CLA on body composition appear to be due in part to reduced fat deposition and increased lipolysis in adipocytes, possibly coupled with enhanced fatty acid oxidation in both muscle cells and adipocytes; however, CLnA modulates the body fat and TG metabolism differently from CLA by an unclear mechanism \[[@r78], [@r79]\]. These associations thus suggest a potential role of these bacterial species in the production of CLA and CLnA in vivo in humans. In fact, it has been demonstrated in vitro that *Bifidobacterium* can produce both CLA and CLnA but that *Eubacterium ventriosum* and *Lactobacillus* only produce CLA \[[@r80], [@r81]\].

### Bile acid derivatives

Primary bile acids, including cholic and chenodeoxycholic acids, are formed from cholesterol in the liver, conjugated to either taurine or glycine, and then excreted into the gastrointestinal tract. They are deconjugated by several gram-positive bacterial species, such as lactobacilli, and after additional microbial modifications create over 50 different secondary bile acids in human feces \[[@r82]\]. Bile acids, which are hydroxylated steroids, contribute to the digestion of dietary lipids in the gut and have a signaling function \[[@r83]\]. Increased primary bile acid biosynthesis has been shown to be associated with obesity; however, higher levels of secondary bile acids are observed in normal-weight individuals \[[@r84]\]. Secondary bile acids affect energy expenditure and glucose homeostasis via their impacts on gluconeogenesis, insulin secretion, and insulin sensitivity \[[@r85]\]. The concentration and composition of bile acids in the gastrointestinal tract can influence carbohydrate and lipid metabolism, so they can alter the rate of weight loss \[[@r86]\]. Aleman *et al.* \[[@r87]\] showed significant positive associations between secondary bile acid metabolism and *Christensenellaceae*. They also reported a negative correlation between *Christensenellaceae* and weight loss \[[@r87]\].

It has been shown that bile acids are the key metabolic mediators between the gut microbiota and the host metabolism \[[@r88]\]. The gut microbiota has a profound effect on bile acid metabolism by promoting deconjugation, dehydrogenation, and dehydroxylation of primary bile acids in the distal small intestine and colon \[[@r41]\]. Bondia-Pons *et al.* \[[@r19]\] showed positive correlations between *Bacteroides* diversity and plasma clusters of the bile acid lithocholic acid (LCA) and phosphatidylethanolamines. Bile acids are predominantly conjugated to glycine in humans and to taurine in mice. They are critical regulators of hepatic lipid and glucose metabolism and influence signaling pathways via two receptors with pleiotropic functions, the nuclear farnesoid X receptor (FXR) and the G protein-coupled bile acid receptor TGR5 \[[@r41]\]. The gut microbiota modulates bile acid synthesis by changing the bile acid pool composition and by alleviating FXR inhibition in the small intestine.

### Metabolites derived from bacterial degradation of carnitine and choline

Trimethylamine *N*-oxide (TMAO) is generated through a two-step pathway that begins with the conversion of dietary nutrients such as phosphatidylcholine, choline, and carnitine into trimethylamine (TMA) by the gut microbiota. TMA then circulates to the liver, where it is oxidized into TMAO. It has been shown that the urinary excretion of metabolites associated with bacterial degradation of choline, such as TMA and dimethylamine (DMA), increased in an obese group \[[@r28]\]. Org *et al.* \[[@r20]\] showed that serum TMAO was positively correlated with *Peptococcaceae* and *Prevotella* but negatively correlated with *Faecalibacterium prausnitzii.* Lower levels of *F. prausnitzii* have been related to increased levels of inflammatory markers, obesity, diabetes, and immune-related diseases \[[@r89]\]. Since higher levels of TMAO are associated with heart failure and chronic kidney disease, recently, research has been focused on the discovery of inhibitors that block TMAO production as a therapeutic strategy to decrease the risk of cardiovascular or kidney disease \[[@r90]\]. It has been found that iodomethylcholine (IMC) and fluoromethylcholine (FMC), choline analogs which irreversibly inhibit microbial choline TMA lyase activity, led to reductions in plasma TMAO level and atherosclerotic lesion development in mice \[[@r91]\]. Regarding the possible role of TMAO in obesity, the full extent of the therapeutic potential of TMAO inhibition in obesity still needs to be investigated.

### Other microbiota-derived metabolites

#### Glycoprotein acetyl

Glycoprotein acetyl, mainly α1-acid glycoprotein (GlycA), is a novel marker of low-grade inflammation that has been shown to increase in obese subjects \[[@r28]\] and obese pregnant women \[[@r22]\]. GlycA includes a complex heterogeneous nuclear magnetic resonance signal containing N-acetyl sugar groups originating from multiple acute phase circulating glycoproteins \[[@r92]\]. It has been shown that GlycA is associated with obesity and insulin resistance \[[@r93], [@r94]\]. Moreover, GlycA was correlated with higher concentrations of triglycerides, LDL-C, and BCAA in obese individuals \[[@r95], [@r96]\]. It was also demonstrated that specific gut bacterial groups were negatively associated with GlycA, which was further related to intake of fiber. Fiber intake was linked negatively with bacteria of the Firmicutes and Bacteroidetes phyla and linked positively with a genus of the Bacteroidetes phylum \[[@r97]\].

#### Hippuric acid

One of the urinary gut bacterial metabolites assessed in two included articles was hippuric acid. Ahmad *et al.* \[[@r28]\] and Calvani *et al.* \[[@r25]\] showed an inverse relationship of hippuric acid with obesity. Hippurate is a gut microbial-mammalian co-metabolite of benzoic acid that can be made by gut *Clostridium* spp. from low-molecular-weight aromatic compounds and polyphenols, conjugated with glycine in the mitochondria, and then excreted in the urine \[[@r98]\]. Other human and animal models of obesity have consistently shown the association of urinary hippurate with leaner phenotypes and an altered gut bacterial composition \[[@r99],[@r100],[@r101]\]. Pallister *et al.* \[[@r102]\] showed that the plasma hippurate concentration was positively associated with the *Ruminococcaceae* and *Rikenellaceae* families and negatively associated with the *Lachnospiraceae* family. Hippurate was significantly associated with gut bacterial diversity, independently of dietary intake in a sample of 1,032 individuals, accounting for 6.5% of the variance in Shannon diversity index. Higher gut bacterial diversity and hippurate level were associated with a reduced risk of having metabolic syndrome \[[@r102]\].

#### Trigonelline

Trigonelline, an alkaloid formed by the methylation of niacin, is excreted in urine. Although trigonelline may have dietary sources, it is mainly biosynthesized by the gut microbiota during the methionine cycle. Decreased urinary level of trigonelline has been shown to be correlated with an alteration in energy and tryptophan metabolism. Calvani *et al.* \[[@r25]\] reported an inverse relationship between urinary trigonelline and obesity, suggesting that oxidative stress possibly has a role in the observed relationship. Trigonelline, a byproduct of the conversion of S-adenosylmethionine to S-adenosylhomocysteine consumed in the regenerating pathway of glutathione stores, is depleted by oxidative stress in obesity \[[@r103]\]. The variations in trigonelline excretion in obesity demonstrate the relationships between gut bacterial composition and function and the obese phenotype.

#### Xanthine

Xanthine is a purine base found in most human body tissues and fluids which is produced in the pathway of purine degradation and ultimately converted to uric acid by the xanthine oxidase enzyme \[[@r104]\]. It is a gut microbiota-derived metabolite that has been shown to decrease in obese individuals. Moreover, a decreased urinary level of xanthine was associated with an increased serum level of uric acid in obese subjects \[[@r25]\].

CONCLUSION {#s5}
==========

In this systematic review, we provided an overview of the role of gut microbiota-derived metabolites in obesity. These metabolites can affect multiple metabolic pathways in the host which lead to obesity. Some of these metabolites consistently decrease in obesity and its related metabolic complications, while others seem to increase as a result of host-microbiome interactions. Metabolomics studies have allowed identification of microbial markers associated with obesity across different populations and subsequently development of therapeutic strategies. Interventional studies with the aim of modulating gut microbiota and consequently the metabolic profile in obesity could also contribute to obesity management. There are various strategies for gut microbiota modulation, including the use of functional foods, probiotics, prebiotics, fecal microbiota transplantation, and bariatric surgery. However, a limited number of studies have assessed the alteration of gut microbiota, their metabolites, and the consequential functional effects after interventions in obesity. Currently, there is no consensus on which type of gut microbiota-modulating interventions will induce a better metabolic profile in obesity. Further studies are needed in this field to develop strategies for modifying the specific gut microbiota-derived metabolites. Moreover, considering the strain-dependent functions of some taxa, more studies are needed to investigate the relationship between gut microbiota and metabolites at the strain level.
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